Reviva Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:RVPH)

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) saw unusually large options trading activity on Thursday. Stock traders purchased 4,052 call options on the stock. This is an increase of approximately 103% compared to the average daily volume of 1,999 call options.

Wall Street Analyst Weigh In

Separately, EF Hutton Acquisition Co. I upgraded shares of Reviva Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 23rd.

Reviva Pharmaceuticals Stock Performance

Reviva Pharmaceuticals stock opened at $2.01 on Friday. The firm has a market capitalization of $67.22 million, a PE ratio of -1.81 and a beta of -0.02. The stock’s 50 day moving average price is $1.46 and its 200 day moving average price is $1.27. Reviva Pharmaceuticals has a one year low of $0.60 and a one year high of $5.67.

Institutional Investors Weigh In On Reviva Pharmaceuticals

A hedge fund recently raised its stake in Reviva Pharmaceuticals stock. Geode Capital Management LLC grew its holdings in shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 17.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 278,496 shares of the company’s stock after buying an additional 42,376 shares during the quarter. Geode Capital Management LLC owned 0.83% of Reviva Pharmaceuticals worth $401,000 as of its most recent SEC filing. 63.18% of the stock is owned by institutional investors and hedge funds.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.